Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthetics Stance In NDI Guidance Raises Red Flag For Industry

This article was originally published in The Tan Sheet

Executive Summary

FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.
Advertisement

Related Content

Herbalife Proposes FDA Use NDI Master Files To Reduce Notification Burden
CHPA Urges Nuanced, Risk-Based Approach To Nanotechnology
FDA Errs On Estimates For NDIs, Claims Substantiation – CRN
NDI Safety Data Guidance Sets Evidence Bar Too High, Attorney Says
NDI Guidance Sparks Questions Even From Firms Ready To Comply
Ovos' Former IND Homotaurine Strikes Out As Dietary Ingredient
FDA Warning Draws Solid Line Between Steroid Products And Supplements
CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More
CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More
Ephedra Rule Cites Lack Of Safety Data In Vulnerable Subjects

Topics

Advertisement
UsernamePublicRestriction

Register

PS105172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel